A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
Public ClinicalTrials.gov record NCT03238963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)
Study identification
- NCT ID
- NCT03238963
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Interventions
- BI 1467335 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2017
- Primary completion
- May 13, 2020
- Completion
- May 13, 2020
- Last update posted
- Jun 3, 2021
2017 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Trinity Research | Dothan | Alabama | 36301 | — |
| Retinal Research Institute, LLC | Phoenix | Arizona | 85053 | — |
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Stanford University Medical Center | Palo Alto | California | 94303 | — |
| Florida Retina Institute | Orlando | Florida | 32806 | — |
| Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Raj K. Maturi, MD PC | Indianapolis | Indiana | 46290 | — |
| Cumberland Valley Retina Consultants, PC. | Hagerstown | Maryland | 21740 | — |
| NJRetina | Teaneck | New Jersey | 07666 | — |
| New York Eye and Ear Infirmary of Mount Sinai | New York | New York | 10003 | — |
| Charlotte Eye Ear Nose and Throat Associates, PA | Charlotte | North Carolina | 28210 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Retina Research Institute of Texas | Abilene | Texas | 79606 | — |
| Retina Research Center, PLLC | Austin | Texas | 78705 | — |
| Retina Consultants of Houston, PA | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03238963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03238963 live on ClinicalTrials.gov.